- Home
- AGEN vs SILC Comparison
AGEN vs SILC Comparison
Compare AGEN & SILC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- SILC
- Stock Information
- Founded
- AGEN 1994
- SILC 1987
- Country
- AGEN United States
- SILC Israel
- Employees
- AGEN N/A
- SILC N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- SILC Computer Manufacturing
- Sector
- AGEN Health Care
- SILC Technology
- Exchange
- AGEN Nasdaq
- SILC Nasdaq
- Market Cap
- AGEN 87.7M
- SILC 85.1M
- IPO Year
- AGEN 2000
- SILC 1994
- Fundamental
- Price
- AGEN $4.66
- SILC $15.82
- Analyst Decision
- AGEN Buy
- SILC Hold
- Analyst Count
- AGEN 4
- SILC 2
- Target Price
- AGEN $13.00
- SILC N/A
- AVG Volume (30 Days)
- AGEN 1.7M
- SILC 11.4K
- Earning Date
- AGEN 08-07-2025
- SILC 07-28-2025
- Dividend Yield
- AGEN N/A
- SILC N/A
- EPS Growth
- AGEN N/A
- SILC N/A
- EPS
- AGEN N/A
- SILC N/A
- Revenue
- AGEN $99,524,000.00
- SILC $58,134,000.00
- Revenue This Year
- AGEN $12.69
- SILC $6.26
- Revenue Next Year
- AGEN N/A
- SILC $19.14
- P/E Ratio
- AGEN N/A
- SILC N/A
- Revenue Growth
- AGEN N/A
- SILC N/A
- 52 Week Low
- AGEN $1.38
- SILC $11.35
- 52 Week High
- AGEN $18.74
- SILC $18.24
- Technical
- Relative Strength Index (RSI)
- AGEN 49.92
- SILC 54.17
- Support Level
- AGEN $4.71
- SILC $14.85
- Resistance Level
- AGEN $5.22
- SILC $15.94
- Average True Range (ATR)
- AGEN 0.36
- SILC 0.47
- MACD
- AGEN -0.12
- SILC 0.05
- Stochastic Oscillator
- AGEN 14.76
- SILC 72.76
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.